Press release
Progressive Familial Intrahepatic Cholestasis (PFIC) Market is projected to reach USD 1.02 billion by 2034
Progressive Familial Intrahepatic Cholestasis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71668
PFIC is a group of rare, autosomal recessive liver disorders caused by defects in bile formation, leading to progressive cholestasis, pruritus, malabsorption, growth failure, and eventual liver failure. The six known subtypes (PFIC1-PFIC6) are linked to pathogenic variants in genes such as ATP8B1, ABCB11, ABCB4, NR1H4, TJP2, and USP53. PFIC often presents in infancy or early childhood and can rapidly progress to cirrhosis and the need for liver transplantation.
The therapeutic landscape has expanded significantly with the introduction of IBAT (ileal bile acid transporter) inhibitors, which reduce bile acid accumulation and improve pruritus and liver biomarkers, providing a non-surgical alternative for many patients.
Key Market Highlights
• 2024 Market Size: USD 412 million
• 2034 Forecast: USD 1.02 billion
• CAGR (2025-2034): 9.4%
• Major Therapeutic Advancement: IBAT inhibitors
• Highest-Burden Region: Middle East & parts of South Asia (higher consanguinity rates)
Market Growth Drivers
1. Increased Use of Genetic Testing
Broader availability of:
• Next-generation sequencing (NGS)
• Panel testing for cholestasis genes
• Prenatal genetic diagnosis
• Carrier screening
has expanded early detection and subtype differentiation.
2. Rise of IBAT Inhibitors
Novel bile acid transport inhibitors significantly reduce pruritus and improve biochemical markers, reducing the need for invasive surgical procedures such as biliary diversion.
3. Expansion of Pediatric Hepatology Expertise
More specialized liver centers and multidisciplinary care models enable earlier referral and improved disease management.
4. Growth in Liver Transplant Programs
Improved surgical techniques and pediatric transplant protocols extend long-term survival for advanced PFIC.
5. Increasing Rare-Disease Awareness
Education campaigns and global PFIC patient networks support early diagnosis and clinical trial participation.
Market Restraints
• Extremely low global prevalence
• High cost of IBAT inhibitors and lifelong treatment
• Delayed diagnosis due to symptom overlap with other cholestatic diseases
• Limited pediatric hepatology resources in low-income regions
• Ongoing need for transplantation in severe variants
Market Opportunities
1. Gene Therapy & Gene Editing
Promising research is targeting PFIC subtypes with genetic correction using AAV vectors and CRISPR platforms.
2. Subtype-Specific Therapeutics
Precision medicines targeting specific transporter defects represent a major unmet opportunity.
3. Expanded Newborn Screening Programs
Early detection could significantly delay or prevent disease progression.
4. Digital Tools for Pruritus Monitoring
Wearables and smartphone-based tools offer objective assessment of symptom severity.
5. Multinational Clinical Trial Expansion
Growing rare-disease networks are improving global trial feasibility and recruitment.
Segmentation Overview
By Disease Type
• PFIC1 (ATP8B1 deficiency)
• PFIC2 (ABCB11 deficiency)
• PFIC3 (ABCB4 deficiency)
• PFIC4-PFIC6 (rare genetic variants)
By Treatment Type
• IBAT inhibitors
• Ursodeoxycholic acid (UDCA)
• Biliary diversion surgery
• Liver transplantation
• Gene therapy (pipeline)
• Nutritional and supportive therapy
By Diagnostic Method
• Genetic testing (NGS, panel testing)
• Liver biopsy
• Serum bile acid profiling
• Imaging (ultrasound, elastography)
By End User
• Pediatric hospitals
• Hepatology/transplant centers
• Genetic testing laboratories
• Research institutions
Explore Full Report here: https://exactitudeconsultancy.com/reports/71668/progressive-familial-intrahepatic-cholestasis-market
Regional Insights
North America - Leading Market
Strong adoption of IBAT inhibitors, advanced pediatric hepatology centers, robust rare-disease infrastructure, and expanding genetic testing access support leadership.
Europe - High Diagnostic Rates
Well-established newborn care systems and active PFIC clinical research provide consistent growth.
Asia Pacific - Fastest-Growing Region
Improved genome diagnostics, rising awareness, and developing pediatric transplant programs expand regional potential.
Middle East - High Prevalence
Consanguinity-driven incidence increases patient volumes, with rising investment in pediatric hepatic care.
Latin America & Africa - Early-Stage but Improving
Diagnosis remains limited, but awareness and referral networks are growing.
Competitive Landscape
Key companies involved in PFIC therapeutics, diagnostics, and research include:
• Albireo Pharma (IBAT inhibitors)
• Mirum Pharmaceuticals
• Pfizer (liver disease platform)
• Novartis
• Gilead Sciences
• Takeda
• Thermo Fisher Scientific (genetic testing technologies)
• Illumina
• Labcorp & Quest Diagnostics
Academic centers are also driving gene therapy research and clinical innovation.
Recent Market Developments
• Rapid global adoption of IBAT inhibitors for pediatric cholestasis
• New research into ABC transporter biology and precision therapy
• Expansion of gene therapy programs targeting PFIC2
• Creation of international PFIC patient registries
• Advances in pediatric liver transplantation outcomes
Future Outlook (2025-2034)
The PFIC market is expected to evolve significantly as:
• IBAT inhibitors expand across PFIC subtypes
• Gene therapies approach clinical maturity
• Newborn screening detects cases earlier
• Global pediatric liver care improves
• Digital monitoring tools enhance long-term management
With strong therapeutic innovation and earlier diagnosis, the market is expected to grow from USD 412 million (2024) to USD 1.02 billion (2034), reflecting robust long-term growth in the rare pediatric liver disorder segment.
This report is also available in the following languages : Japanese (進行性家族性肝内胆汁うっ滞症市場), Korean (진행성 가족성 간내 담즙 정체 시장), Chinese (进行性家族性肝内胆汁淤积症市场), French (Marché de la cholestase intrahépatique familiale progressive), German (Markt für progressive familiäre intrahepatische Cholestase), and Italian (Mercato della colestasi intraepatica familiare progressiva), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71668
Our More Reports:
Primary Progressive Multiple Sclerosis (PPMS) Market
https://exactitudeconsultancy.com/reports/72071/primary-progressive-multiple-sclerosis-ppms-market
Secondary Progressive Multiple Sclerosis Market
https://exactitudeconsultancy.com/reports/72072/secondary-progressive-multiple-sclerosis-market
IR Corrected Lenses Market
https://exactitudeconsultancy.com/reports/75305/ir-corrected-lenses-market
Electric Submersible Pump & Artificial lift Systems Market
https://exactitudeconsultancy.com/reports/75678/electric-submersible-pump-artificial-lift-systems-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Progressive Familial Intrahepatic Cholestasis (PFIC) Market is projected to reach USD 1.02 billion by 2034 here
News-ID: 4307746 • Views: …
More Releases from Exactitude Consultancy
Cold Planer Market Sees Consistent Growth Supported by Global Road Rehabilitatio …
The global cold planer market is experiencing steady growth as governments and private contractors increase spending on road rehabilitation, resurfacing, and infrastructure modernization. Cold planers, also known as milling machines, are widely used to remove damaged asphalt and concrete surfaces efficiently, supporting sustainable road construction practices.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68250
Key Market Highlights
• Increasing focus on road maintenance and resurfacing projects
• Growing demand for efficient and precision milling…
Credit Management Software Market Accelerates as Organizations Focus on Risk Mit …
The global credit management software market is witnessing robust growth as organizations across industries adopt digital solutions to manage credit risk, improve receivables performance, and strengthen financial controls. Credit management software enables businesses to automate credit scoring, monitor customer creditworthiness, and streamline collections processes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68248
Key Market Highlights
• Growing adoption of automated credit risk assessment tools
• Increasing focus on working capital and cash flow management
• Integration…
Session Border Controller Market Expands Rapidly as Enterprises and Telecom Oper …
The global session border controller (SBC) market is experiencing strong growth as telecom operators and enterprises increasingly deploy SBC solutions to secure, manage, and optimize real-time IP communications. SBCs play a critical role in protecting voice over IP (VoIP), unified communications (UC), and multimedia sessions from cyber threats while ensuring interoperability and quality of service.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68246
Key Market Highlights
• Growing adoption of VoIP and…
Biofuel Market Including E-Methane and Sustainable Aviation Fuel Gains Strong Tr …
The global biofuel market, encompassing e-methane, sustainable aviation fuel (SAF), and other advanced biofuels, is witnessing robust growth as governments and industries intensify efforts to reduce carbon emissions and transition toward cleaner energy sources. These fuels play a critical role in achieving net-zero targets while enabling decarbonization of hard-to-abate sectors such as aviation, shipping, and heavy transportation.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68244
Key Market Highlights
• Rapid growth of…
More Releases for PFIC
Progressive Familial Intrahepatic Cholestasis (PFIC) Market Growth, Trends, Cons …
Introduction
Progressive Familial Intrahepatic Cholestasis (PFIC) is a group of rare, inherited liver disorders characterized by defective bile secretion, leading to chronic cholestasis, liver damage, and progressive liver failure. PFIC typically manifests in infancy or early childhood and, without intervention, often requires liver transplantation at a young age.
For decades, treatment options were limited to symptomatic relief and surgical interventions. However, with the approval of bile acid transporter inhibitors, alongside the emergence…
Progressive Familial Intrahepatic Cholestasis Pipeline: Promising Therapies Shap …
The treatment landscape for Progressive Familial Intrahepatic Cholestasis (PFIC), a rare and progressive liver disorder, is evolving rapidly, driven by innovative therapies from leading pharmaceutical and biotech companies. Key players such as Mirum Pharmaceuticals and Vivet Therapeutics are advancing therapeutic options focused on addressing the root causes of cholestasis, including bile acid regulation and hepatic transport. These emerging treatments aim to improve liver function, reduce pruritus, and delay the progression…
Progressive Familial Intrahepatic Cholestasis Treatment Market worth $156.14 mil …
The "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.
Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/progressive-familial-intrahepatic-cholestasis-treatment?utm_source=openpr&utm_medium=referral&utm_campaign=sample
Progressive Familial Intrahepatic Cholestasis (PFIC) encompasses rare genetic disorders impairing liver bile secretion, leading to cholestasis, liver disease, and potential liver failure. The treatment market for PFIC includes pharmacological therapies, surgical…
Progressive Familial Intrahepatic Cholestasis (PFIC) Market to Register Sustaina …
The Progressive Familial Intrahepatic Cholestasis (PFIC) market is undergoing significant advancements in diagnosis and treatment options, aiming to address the complex needs of patients with these rare genetic disorders. Emerging therapies targeting specific genetic mutations associated with PFIC show promise in slowing disease progression and improving quality of life. Additionally, increased awareness among healthcare professionals and improved diagnostic tools are facilitating earlier detection and intervention, enhancing patient outcomes.
DelveInsight's "Progressive…
Progressive Familial Intrahepatic Cholestasis (PFIC) Market on the Verge of Extr …
As per DelveInsight, the Progressive Familial Intrahepatic Cholestasis Market is anticipated to evolve immensely in the coming years owing to the rise in number of prevalent cases and the launch of new therapies in the market.
DelveInsight's "Progressive Familial Intrahepatic Cholestasis (PFIC) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Familial Intrahepatic Cholestasis Market Size…
Progressive Familial Intrahepatic Cholestasis (PFIC) Market to Register Immense …
As per DelveInsight, the Progressive Familial Intrahepatic Cholestasis Market is anticipated to evolve immensely in the coming years owing to the rise in number of prevalent cases and the launch of new therapies in the market.
DelveInsight's "Progressive Familial Intrahepatic Cholestasis (PFIC) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Familial Intrahepatic Cholestasis Market…
